【个人简介】
李仕颖，男，研究员，分子药剂生物学研究室主任、药学院教工第四党支部书记。2017年毕业于武汉大学生物医用高分子材料教育部重点实验室，同年加入广州医科大学药学院分子与临床药理研究所工作。主持中国科协“青年人才托举工程”，广东省自然科学基金-杰出青年科学基金，国家重点研发计划项目（课题负责人），国家自然科学基金-面上、青年科学基金目，广东省普通高校重点领域-生物医药与健康重点领域专项，广州市科技计划-科技菁英“领航”项目、一般项目等课题，参与国家自然科学基金-重点项目、面上项目、青年科学基金项目等课题。以通讯作者在 ACS Nano，Nano Lett.，Adv. Funct. Mater.，Acta Pharm. Sin. B，Biomaterials，J. Control. Release，Adv. Sci.，Small等杂志发表SCI论文80余篇，获授权国家发明专利8项。现任《Acta Pharm. Sin. B》、《Chinese Chem. Lett.》、《Asian J. Pharm. Sci.》、《药学学报》青年编委，《Pharmaceutics》客座编辑，担任Adv. Mater.，Nano Today，Mater. Today，ACS Nano，Adv. Sci.，Adv. Funct. Mater.，Biomaterials，Acta Pharm. Sin. B等100余个学术期刊独立通讯评审。任中国药理学会表观遗传专业委员会委员，广东省药理学会心血管专业委员会委员，中国抗癌协会纳米肿瘤学专业委员会青年委员。任国家自然科学基金、中国博士后科学基金、广东省自然科学基金、广东省教育厅等项目和奖励评审。荣获2023年广州科技创新南山奖-青年科技人才南山奖，2023华夏医学科技奖-三等奖，2023年中国产学研合作创新成果奖-优秀奖，2020年广东省科技进步奖-一等奖，2020年广东省药理学会科技成果奖-一等奖等奖励和荣誉。
【联系邮箱】
lisy-sci@gzhmu.edu.cn
【研究方向类别】
1、学术学位：药剂学
2、专业学位：工业药学（临床药剂学）
【具体研究方向】
药物递送载体与吸入制剂
【主要科研项目】
1. 国家自然科学基金-面上项目（32371394），50万元，主持；
2. 广州市科技计划-科技菁英“领航”项目（2024A04J6616），30万元，主持；
3. 广东省基础与应用基础研究基金东莞市联合基金（粤莞联合基金）项目（2023A1515140078），12万元，项目联合负责人；
4. 国家重点研发计划-青年科学家项目（2021YFD1800600），80万元，课题负责人；
5. 中国科协第四届“青年人才托举工程”项目（2018QNRC001），主持；
6. 广东省自然科学基金-杰出青年科学基金项目（2021B1515020043），主持；
7. 广州医科大学“国家杰出青年及优秀青年科学基金培育计划”项目，主持；
8. 国家自然科学基金-青年科学基金（51802049），27万元，主持；
9. 广东省普通高校重点领域-生物医药与健康重点领域专项项目（2022ZDZX2046），15万元，主持；
10. 广州市科技计划-一般项目（201904010324），20万元，主持；
【所获荣誉和奖励】
1. 2023年广州科技创新南山奖-青年科技人才南山奖（1/1）；
2. 2023年华夏医学科技奖-三等奖（2/9）；
3. 2023年度获《药学学报》优秀青年编委；
4. 2023年中国产学研合作创新成果奖-优秀奖（2/15）。
5. 2022年度获《药学学报》优秀青年编委；
6. 2022年获广州医科大学药学院建院十周年“优秀青年奖”；
7. 2021年广州医科大学-青年岗位能手；
8. 2020年广东省科技进步一等奖（排名第6/8）；
9. 2020年广东省药理学会科技成果一等奖（排名第2/9）；
10. 2019年获“第五届药学前沿论坛暨第四届表观遗传与生物医药研发国际学术大会”-药学青年论坛三等奖；
11. 2019年度《Acta Pharm. Sin. B》优秀审稿人；
12. 2018年广州医科大学黄大年式教师团队；
【主要论文及著作（代表性）】
1. Chen Y, Cen Y, Li X X, Ou X C, Chen X Y, Yan M Y, Shao Z C, Wang T X, Guo N, Yu R*, Li S Y*. Chimeric peptide engineered polyprodrug enhances cytotoxic T cell response by inducing immunogenic cell death and upregulating major histocompatibility complex-class I. ACS Nano 2024.【JCR一区, IF: 15.8】
2. Zheng R R, Yang N, Li Q Y, Chen Z X, Huang C Y, Zhao L P, Chen X, Li S Y*. Chimeric peptide engineered immunostimulant for endoplasmic reticulum targeted photodynamic immunotherapy against metastatic tumor. J. Control. Release 2024, 374, 230-241.【JCR一区, IF: 10.5】
3. Zheng R R, Huang C Y, Zhou H Y, Zhao L X, Li Q Y, Chen G M, Zhao L P*, Li S Y*. Multi-synergistic chemotherapeutic drug assemblies to activate colorectal cancer immunotherapy by modulating the multilevel immunosuppressive characteristics. Aggregate 2024, e610.【JCR一区, IF: 13.9】
4. Wei Y X, Chen Z X, Huang C Y, Cheng H*, Jiang X F*, Li S Y*. A breast cancer targeted photodynamic degrader to activate immunotherapy through EGFR degradation mediated PD-L1 downregulation. Chem. Eng. J. 2024, 488, 150822. 【JCR一区, IF: 13.3】
5. Zhang W, Yu B X, Chen X Y, Yan M Y, Liu Q Q, Liu Y B, Yang N, Cai H, Yan N, Kong R J, Cheng H*, Li S Y*, Chen A L*. Tumor homing chimeric peptide rhomboids to improve photodynamic performance by inhibiting therapy-upregulated cyclooxygenase-2. Small 2024, 2309882. 【JCR一区, IF: 13.0】
6. Yu B X, Liu Y B, Chen X Y, Zhang W, Cen Y, Yan M Y, Liu Q Q, Li S Y*. Self assembled PD-L1 downregulator to boost photodynamic activated tumor immunotherapy through CDK5 inhibition. Small 2024, 2311507. 【JCR一区, IF: 13】
7. Yan M Y, Chen X Y, Liu Q Q, Yu B X, Cen Y, Zhang W, Liu Y B, Li X X, Chen Y, Wang T*, Li S Y*. Transferrin targeted immunostimulant for photodynamic immunotherapy against metastatic tumors through β-catenin/CREB interruption. APSB 2024, 14, 4118-4133. 【JCR一区, IF: 14.7】
8. Cen Y, Chen Y, Li X X, Chen X Y, Yu B X, Yan M Y, Li S Y*. Optical controlled and nuclear targeted CECR2 competitor to downregulate CSF-1 for metastatic breast cancer immunotherapy. Biomaterials 2024, 308, 122568. 【JCR一区, IF: 12.8】
9. Zhao L P, Zheng R R, Rao X N, Huang C Y, Zhou H Y, Yu X Y, Jiang X Y, Li S Y*. Chemotherapies-enabled colorectal cancer immunotherapy of self-delivery nano-PROTACs by inhibiting tumor glycolysis and avoiding adaptive immune resistance. Adv. Sci. 2024, 11, 2309204.【JCR一区, IF: 14.3】
10. Liu Y B, Chen X Y, Yu B X, Cen Y, Huang C Y, Yan M Y, Liu Q Q, Zhang W, Li S Y*, Tang Y Z*. Chimeric peptide engineered self-delivery nanomedicine for photodynamic triggered breast cancer immunotherapy by macrophage polarization. Small 2024, 2309994. 【JCR一区, IF: 13.0】
11. Liu Q Q, Chen X Y, Jiang Y, Yan M Y, Yu B X, Zhang W, Cen Y, Zhang J Y, Zhang J, Lei Q*, Li S Y*, Yang B*. Self-promoted targeting delivery of nanodrug through chemotherapeutic upregulation of CD47 for triple negative breast cancer therapy. Adv. Funct. Mater. 2024, 34, 2311677.【JCR一区, IF: 18.5】
12. Li X T, Peng S Y, Feng S M, Bao T Y, Li S Z, Li S Y*. Recent progress in phage-based nanoplatform for tumor therapy. Small 2024, 20, 2307111.【JCR一区，IF: 13.0】
13. Chen A L, Yang N, Zhang W, Zheng R R, Yu R, Kong R J, Wang Y Q, Cheng H, Yu X Y, Li S Y*. Pyroptosis induction synergized with IDO inhibition of ternary biomedicine for photodynamic activated tumor immunotherapy. Chem. Eng. J. 2023, 478, 147465. 【JCR一区，IF: 13.3】
14. Chen X Y, Yan M Y, Liu Q Q, Yu B X, Cen Y, Li S Y*. Chimeric peptide engineered bioregulator for metastatic tumor immunotherapy through macrophage polarization and phagocytosis restoration. ACS Nano 2023, 17, 16056-16068.【JCR一区，IF: 15.8】
15. Zhao L P, Rao X N, Zheng R R, Huang C Y, Kong R J, Cheng H*, Li B*, Li S Y*. Carrier-free nano-PROTACs to amplify photodynamic therapy induced DNA damage through BRD4 degradation. Nano Lett. 2023, 23, 6193-6201.【JCR一区，IF: 9.6】
16. Cen Y, Chen X Y, Liu Y B, Yu B X, Yan M Y, Yang N, Kong R J, Li S Y*, Ti H H*, Cheng H*. Drug induced mitochondria dysfunction to enhance photodynamic therapy of hypoxic tumors. J. Control. Release 2023, 358, 654-666.【JCR一区，IF: 10.5】
17. Zheng R R, Zhao L P, Huang C Y, Cheng H, Yang N, Chen Z X, Cai H, Zhang W, Kong R J, Li S Y*. Paraptosis inducer to effectively trigger immungenic cell death for metastatic tumor immunotherapy with IDO inhibition. ACS Nano 2023, 17, 9972-9986.【JCR一区，IF：15.8】
18. Zhao L P, Rao X N, Zheng R R, Huang C Y, Kong R J, Yu X Y*, Cheng H*, Li S Y*. Targeting glutamine metabolism with photodynamic immunotherapy for metastatic tumor eradication. J. Control. Release 2023, 357, 460-471.【JCR一区, IF: 10.5】
19. Li X T, Chen L, Huang M T, Zeng S T, Zeng J Y, Peng S Y, Wang Y Q, Cheng H*, Li S Y*. Innovative strategies for photodynamic therapy against hypoxic tumors. Asian J. Pharm. Sci. 2023, 18, 100775. 【JCR一区, IF: 10.7】
20. Chen S Y, Zhao L P, Chen Z X, Huang C Y, Wang Y Q, Zhang D W*, Li S Y*, Ti H H*, Cheng H*. Self-delivery biomedicine for enhanced photodynamic therapy by feedback promotion of tumor autophagy. Acta Biomater. 2023, 158, 599-610.【JCR一区，IF : 9.4】
21. Zhao L P, Rao X N, Huang C Y, Zheng R R, Kong R J, Chen Z X, Yu X Y*, Cheng H*, Li S Y*. Epigenetic reprogramming of carrier free photodynamic modulator to activate tumor immunotherapy by EZH2 inhibition. Biomaterials 2023, 293, 121952.【JCR一区，IF: 12.8】
22. Zheng R R, Zhao L P, Yang N, Chen Z X, Kong R J, Huang C Y, Rao X N, Chen X*, Cheng H*, Li S Y*. Cascade immune activation of self delivery biomedicine for photodynamic immunotherapy against metastatic tumor. Small 2023, 19, 2205694.【JCR一区，IF：13.0】
23. Zhao L P, Huang C Y, Zheng R R, Rao X N, Kong R J, Guan R T, Chen Z X, Yu X Y, Cheng H*, Li S Y*. Photodynamic amplified immune checkpoint-blockade therapy of self-delivery bioregulator via epigenetic reprogramming. Chem. Eng. J. 2023, 453, 139729.【JCR一区，IF: 13.3】
24. Zhao L P, Chen S Y, Zheng R R, Rao X N, Kong R J, Huang C Y, Liu Y B, Tang Y Z*, Cheng H*, Li S Y*. Photodynamic initiated ferrotherapy of self-delivery nanomedicine to amplify lipid peroxidation via GPX4 inactivation. ACS Appl. Mater. Interfaces 2022, 14, 53501-53510.【JCR二区，IF: 8.3】
25. Zhao L P, Zheng R R, Huang C Y, Rao X N, Yang N, Chen A L, Yu X Y*, Cheng H*, Li S Y*. Self-delivery ternary bioregulators for photodynamic amplified immunotherapy by tumor microenvironment reprogramming. ACS Nano 2022, 16, 1182-1197.【JCR一区，IF：15.8】
26. Chen X Y, Zheng R R, Zhao L P, Kong R J, Yang N, Liu Y B, Chen A L, Wang C*, Cheng H*, Li S Y*. Photodynamic therapy initiated immunotherapy of self-delivery re-educator by inducing immunogenic cell death and macrophage polarization. Chem. Eng. J. 2022, 435, 134783.【JCR一区，IF：13.3】
27. Deng F A, Yan M Y, Liu Y B, Wang R X, He H Q, Chen A L, Wang J J, Xu L, Cheng H*, Li S Y*. Self-delivery of metal-coordinated mitochondria protonophore uncoupler for O2-exhausting enhanced bioreductive therapy. Biomaterials 2022, 286, 121576. 【JCR一区，IF: 12.8】
28. Zhao L P, Chen S Y, Zheng R R, Kong R J, Rao X N, Chen A L, Cheng H*, Zhang D W*, Li S Y*, Yu X Y*. Self-delivery nanomedicine for glutamine-starvation enhanced photodynamic tumor therapy. Adv. Health. Mater. 2022, 11, 202102038. 【JCR一区，IF: 10】
29. Zhang W L, Chen H Q, Ding L Y, Gong J W, Zhang M R, Guo W Y, Xu P Y*, Li S Y*, Zhang Y L*. Trojan horse delivery of 4,4`-dimethoxychalcone for parkinsonian neuroprotection. Adv. Sci. 2021, 8, 2004555.【JCR一区，IF：14.3】
30. Fan G L, Deng F A, Zhou X, Liu L S, Huang J Q, Zhang D W, Sun Y X, Chen A L*, Cheng H*, Li S Y*. Plasma membrane targeted photodynamic O2 economizer for hypoxic tumor therapy. Biomaterials 2021, 273, 120854.【JCR一区，IF: 12.8】
31. Li X Y, Deng F A, Zheng R R, Liu L S, Liu Y B, Kong R J, Chen A L, Yu X Y, Li S Y*, Cheng H*. Carrier free photodynamic synergists for oxidative damage amplified tumor therapy. Small 2021, 17, 2102470.【JCR一区，IF: 13.3】
32. Zhao L P, Zheng R R, Liu L S, Chen X Y, Guan R T, Yang N, Chen A L, Yu X Y*, Cheng H*, Li S Y*. Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy. Biomaterials 2021, 275, 120970.【JCR一区，IF: 12.8】
33. Zheng R R, Zhao L P, Chen X Y, Liu L S, Liu Y B, Chen X T, Wang C, Yu X Y, Cheng H*, Li S Y*. Metal-coordinated nanomedicine for combined tumor therapy by inducing paraptosis and apoptosis. J. Control. Release 2021, 336, 159-168.【JCR一区，IF: 10.5】
34. Zhao L P, Zheng R R, Huang J Q, Chen X Y, Deng F A, Liu Y B, Huang C Y, Yu X Y*, Cheng H*, Li S Y*. Self-delivery photo-immune stimulators for photodynamic sensitized tumor immunotherapy. ACS Nano 2020, 14, 17100-17113.【JCR一区，IF：15.8】
35. Zhao L P, Zheng R R, Fan G L, Fan J H, Yuan P, Liu L S, Qiu X Z, Yu X Y*, Cheng H*, Li S Y*. Self-delivery nanomedicine for O2-economized photodynamic tumor therapy. Nano Lett. 2020, 20, 2062-2071.【JCR一区，IF：9.6】
36. Yuan P, Fan G L, Fan J H, Zhao L P, Liu L S, Deng F A, Jiang X Y, Hu A H, Yu X Y, Chen A L*, Cheng H*, Li S Y*. Tumor targeted self-synergistic nanoplatforms for aresnic sensitized photodynamic therapy. Acta Biomater. 2020, 117, 349-360.【JCR一区，IF: 9.7
37. Cheng H, Fan G L, Fan J H, Yuan P, Deng F A, Qiu X Z, Yu X Y, Li S Y*, Epigenetics-inspired photosensitizer modification for plasma membrane-targeted photodynamic tumor therapy. Biomaterials 2019, 224, 119497.【JCR一区，IF: 12.8】
38. Cheng H, Fan J H, Zhao L P, Fan G L, Zheng R R, Qiu X Z, Yu X Y*, Li S Y*, Zhang X Z. Chimeric peptide engineered exosomes for dual-stage light guided plasma membrane and nucleus targeted photodynamic therapy. Biomaterials 2019, 211, 14-24.【JCR一区，IF: 12.8】
39. Cheng H, Zheng R R, Fan G L, Fan J H, Zhao L P, Jiang X Y, Yang B, Yu X Y*, Li S Y*, Zhang X Z. Mitochondria and plasma membrane dual-targeted chimeric peptide for single-agent synergistic photodynamic therapy. Biomaterials 2019, 188, 1-11.【JCR一区，IF: 12.8】
40. Cheng H*, X Y Jiang, Zheng R R, Zuo S J, Zhao L P, Fan G L, Xie B R, Yu X Y, Li S Y*，Zhang X Z. A biomimetic cascade nanoreactor for tumor targeted starvation therapy amplified chemotherapy. Biomaterials 2019, 195, 75-85.【JCR一区，IF: 12.8】
